Last updated: 2026-09-23 15:19:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Immuneering Corporation (IMRX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.49, with a market capitalization of $287.26M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.86 to $9.65. This page covers its latest market performance, valuation, price trends and company information.
$287.26M | |
$4.62 | |
$33.99 | |
$0.04 | |
$4.61 | |
185.67K | |
910.87K | |
-- | |
$9.65 | |
$3.86 | |
-- | |
-- |
Immuneering Corporation (IMRX) is currently trading at $4.49 as of 2026-09-23 15:17:00, down 2.71% ($0.13) from the previous close of $4.61
During today's regular trading session, IMRX has traded between $0.04 and $33.99, with a trading volume of 185.67K shares. The current price is near the lower end of today's range.
Over the past seven days, Immuneering Corporation (IMRX) moved from $4.33 to $4.49, representing a gain of 3.58% ($0.16).
The stock traded between $4.24 and $4.71 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 720.28 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 10.8%
IMRX is currently trading at $4.49, placing it 10.8% of the way from its 52-week low of $3.86 to its 52-week high of $9.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 57 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immuneering Corporation (IMRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.